OrbiMed's TKI play makes its Nasdaq debut as Theseus prices IPO
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
A Boston biotech with a hefty backing from OrbiMed is making its Nasdaq debut Thursday.
Theseus Pharmaceuticals priced its IPO at $16 per share, the high end of its range, jumping to the public market roughly six months after OrbiMed led the biotech’s nine-figure Series B. Theseus netted $160 million for the public offering, bringing the sector’s total combined 2021 raise to $13.74 billion across 86 different companies, per the Endpoints News tally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.